InvestorsHub Logo
Followers 20
Posts 2270
Boards Moderated 0
Alias Born 05/04/2005

Re: None

Tuesday, 03/29/2022 7:14:26 AM

Tuesday, March 29, 2022 7:14:26 AM

Post# of 334
In a report released today, Keay Nakae from Chardan Capital reiterated a Hold rating on Exicure (XCUR – Research Report), with a price target of $0.25. The company's shares closed last Monday at $0.20, close to its 52-week low of $0.14. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 11.8% and a 43.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Exicure.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XCUR News